Drug-maker Glenmark said its consolidated net profit - at Rs 128 crore for the quarter ended June 30 - was up 64 per cent, compared with Rs 78 crore in the corresponding previous quarter.
The company recorded good growth in both generics and specialty formulations businesses across geographies, said Glenn Saldanha, Chairman and Managing Director. “We continue to do well in markets like India, US and Russia despite challenges in the operating environment,” he added.
The company posted a consolidated revenue of Rs 1,237 crore in the period under review, up 19 per cent from Rs 1,040 crore in the year-ago period. Revenue from its generic drugs business was at Rs 624 crore (Rs 530 crore). The specialty drugs business, excluding outlicensing revenue was Rs 607 crore (Rs 504 crore), up 20 per cent, the company said.